Brookings, SD– In an effort to accelerate the generation of new knowledge that will advance the health and wellbeing of both animals and humans, RTI has recently hired Dr. Kipp Erickson, PhD as Chief Operating Officer.
Erickson earned his PhD in Cardiopulmonary Physiology from the College of Veterinary Medicine at Kansas State University, and has served most of his professional career as a scientist and leader in both human and animal health drug discovery and product development. Erickson brings significant knowledge and experiences from his time at Procter & Gamble Pharmaceuticals, Pharmacia, Pfizer, Zoetis, and, recently, as VP of Technology at the synthetic biology company, Intrexon. He is well-connected to the industry, and has extensive experience in pharma/biopharma research and product development, strategy and business development, commercialization, licensing, and patenting.
Erickson is also an expert resource toward product concept development and creation of intellectual property, recognizing opportunities from faculty research and how to evolve them toward invention disclosures, and forming connections with potential external partners.
Dr. Erickson hopes to bring new knowledge to the RTI team and further advance growth opportunities in the animal health industry during his time with RTI.